Pregnenolone for Alcoholism

Recruiting at 1 trial location

Overseen By Rajita Sinha, PHD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Yale University

Must not be taking: Opioids, Anticonvulsants, Sedatives, others

Disqualifiers: Substance use disorders, Psychotic disorders, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 25

Duration: 12 weeks

150 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether pregnenolone, a natural hormone, can safely and effectively help individuals with Alcohol Use Disorder (AUD) reduce alcohol consumption. Participants will randomly receive either pregnenolone or a placebo (a pill with no active ingredients) daily for 12 weeks, followed by a check-up a month later. The trial seeks individuals who drink alcohol at least three times a week and meet the criteria for moderate to severe AUD. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

Will I have to stop taking my current medications?

The trial requires you to stop using certain medications like opioids, anticonvulsants, sedatives, and some steroid medications. However, stable prescribed medications for conditions like high blood pressure, heart issues, diabetes, depression, and anxiety may be allowed after review by the study physician.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that pregnenolone is generally safe for people. This treatment is a natural steroid produced by the body to help generate other hormones. It often appears in supplements, usually at lower doses than those tested in this trial.

Some studies have found that pregnenolone users might experience minor side effects, such as headaches, dizziness, or stomach issues. However, these side effects are uncommon and usually mild.

Since pregnenolone is in a Phase 2 trial for this study, it has already passed initial safety tests. This indicates it is safe enough for testing in larger groups. While this doesn't guarantee the absence of side effects, it suggests reasonable safety based on earlier research. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for alcoholism?

Researchers are excited about pregnenolone for treating alcoholism because it offers a fresh approach compared to standard treatments like naltrexone or acamprosate. Unlike these existing options, pregnenolone is a naturally occurring neurosteroid that may help regulate mood and stress, potentially reducing alcohol cravings. This unique mechanism of action targets the brain's stress response systems, providing a novel way to address the underlying issues of alcohol dependence. Additionally, being a natural compound, pregnenolone might offer a different side effect profile, making it an attractive option for individuals seeking alternatives to conventional medications.

What evidence suggests that pregnenolone might be an effective treatment for Alcohol Use Disorder?

This trial will compare pregnenolone with a placebo to evaluate its effectiveness for Alcohol Use Disorder (AUD). Studies have shown that pregnenolone can help reduce stress-related and alcohol-triggered cravings in people with AUD. It may also help balance the body's stress response, which is often disrupted in those with AUD. Some research suggests it might decrease heavy drinking episodes and improve overall well-being. However, other studies found no significant effect on alcohol consumption and preference. These mixed results indicate that while pregnenolone shows promise, more research is needed to fully understand its effectiveness for AUD. ^{6 7 8 9 10}

Are You a Good Fit for This Trial?

This trial is for English-speaking adults aged 18-70 with Alcohol Use Disorder, confirmed by a positive alcohol test or reports from close contacts. Participants must consent to the study's procedures. Pregnant or nursing women, individuals not using effective birth control, opiate users, those on psychoactive drugs including anxiolytics, naltrexone or antabuse, and people with severe medical conditions or low blood pressure are excluded.

Inclusion Criteria

Subjects must meet current Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria for alcohol use disorder; documented positive urine toxicology screen for alcohol at intake or collateral information from family members, significant others, room-mates etc., on recent use

Subject has voluntarily given informed consent and signed the informed consent document

Able to read English and complete study evaluations

Exclusion Criteria

Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study

Meet current criteria for use disorder on another psychoactive substance, such as, heroin, amphetamines, hallucinogens/Phencyclidine (PCP), excluding alcohol and nicotine

Any current use of opiates or past history of opiate use disorder (assessed via urine toxicology and self report)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 300mg pregnenolone or placebo daily for 12 weeks, with bi-weekly assessments and behavioral counseling

12 weeks

24 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Placebo
• Pregnenolone

Trial Overview

The trial tests Pregnenolone (300 mg/day) against a placebo over 12 weeks plus follow-up in treating Alcohol Use Disorder. It's a Phase 2 randomized controlled trial where participants are randomly assigned to receive either the hormone treatment or an inactive substance without knowing which one they're getting.

How Is the Trial Designed?

Group I: patients receiving 300mg PREG Active Control 1 Intervention

Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.

Group II: placebo Placebo Group 1 Intervention

Patients randomly assigned to receive a placebo daily.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborator

Trials

865

Recruited

1,091,000+

Published Research Related to This Trial

The study identified two metabolites, 7 alpha-hydroxy-PREG and 7 beta-hydroxy-PREG, produced in mouse brain microsomes, with different kinetic properties indicating distinct enzymatic pathways for their production.

Different cytochrome P450 (CYP) enzymes are involved in the hydroxylation of pregnenolone, with specific inhibitors revealing that 7 alpha-hydroxylation is primarily inhibited by certain compounds, while 7 beta-hydroxylation involves CYP 1A1 and other unidentified enzymes, providing insights for future research on these metabolic processes in the brain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of cytochrome P450 inhibitors and of steroid hormones on the formation of 7-hydroxylated metabolites of pregnenolone in mouse brain microsomes. Doostzadeh, J., Morfin, R.[2019]

In a study of post-mortem brain samples from 14 alcoholics and 10 non-alcoholic controls, significant increases in the steroid hormones DHEA and pregnenolone (PREGN) were found in alcoholics, particularly in key brain regions like the nucleus accumbens and anterior cingulate cortex.

The study also revealed a negative correlation between PREGN levels and μ-opioid receptor binding, suggesting a potential link between altered steroid hormone levels and the opioid system in the context of alcoholism.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics. Kärkkäinen, O., Häkkinen, MR., Auriola, S., et al.[2018]

In a study involving cynomolgus monkeys, naloxone increased pregnenolone (PREG) levels, while corticotropin-releasing factor (CRF) appeared to enhance the conversion of PREG to deoxycorticosterone (DOC), indicating a complex regulation of PREG by the HPA axis.

Dexamethasone reduced PREG levels despite increasing cortisol, and changes in PREG levels were linked to alcohol intake, suggesting that PREG responses could be a potential marker for alcohol consumption behaviors in non-human primates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Plasma pregnenolone levels in cynomolgus monkeys following pharmacological challenges of the hypothalamic-pituitary-adrenal axis. Porcu, P., Rogers, LS., Morrow, AL., et al.[2013]

In a study with 17 volunteers, pregnenolone was found to be well-tolerated but did not significantly affect mood, memory, or sleep quality over a 4-week period.

In a follow-up study with 11 participants, those pre-treated with pregnenolone experienced significantly less sedation from diazepam, suggesting that pregnenolone may counteract some effects of benzodiazepines, indicating a potential for enhancing arousal.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Meieran, SE., Reus, VI., Webster, R., et al.[2019]

Pregnenolone significantly reduced ethanol self-administration in alcohol-preferring rats without causing locomotor impairment, suggesting its potential as a treatment for alcohol abuse.

Ganaxolone showed a complex effect on ethanol reinforcement, increasing self-administration at low doses but decreasing it at high doses, along with a reduction in locomotor activity at the highest dose.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats. Besheer, J., Lindsay, TG., O'Buckley, TK., et al.[2021]

Allopregnanolone, a neuroactive steroid, shows promise as a therapeutic option for treating symptoms of alcohol use disorders (AUDs), supported by both basic science and clinical evidence.

The review highlights the importance of understanding how allopregnanolone and its precursor, pregnenolone, may help regulate stress and immune responses related to AUDs, while also addressing potential risks and management strategies for therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies. Morrow, AL., Boero, G., Porcu, P.[2021]

Acute administration of pregnenolone significantly reduced alcohol intake and preference in alcohol-preferring rats, particularly at doses of 50 mg/kg and 75 mg/kg, indicating its potential to modulate alcohol consumption behavior.

Chronic treatment with pregnenolone over 10 days did not show significant effects on alcohol intake or preference, suggesting that while it may have short-term benefits, its long-term efficacy for treating alcoholism may be limited.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessment of pregnenolone effects on alcohol intake and preference in male alcohol preferring (P) rats. Rezvani, AH., Levin, ED.[2014]

Citations

1.

reporter.nih.gov

reporter.nih.gov/search/0w6K2fL1oUWihwS-LdtZwg/project-details/10894267

Pregnenolone for the Treatment of Alcohol Use Disorder

Positive findings will support the use of pregnenolone to reduce heavy drinking outcomes and improve functioning among individuals with AUD. NIH Spending ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10630889/

Pregnenolone effects on provoked alcohol craving, anxiety ...

Findings indicate that pregnenolone decreases stress- and alcohol cue-provoked craving and normalizes HPA axis and autonomic arousal in individuals with AUD.

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05781009?term=PREGNENOLONE&rank=3

Pregnenolone for the Treatment of Alcohol Use Disorder

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure.

4.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S0074774224000898

Emerging evidence for pregnane steroid therapeutics ...

In addition, we present evidence that pregnane neuroactive steroids moderate many of the co-occurring symptoms of alcohol addiction, including anxiety, ...

5.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S0014299914005214

Assessment of pregnenolone effects on alcohol intake and ...

In chronic experiments pregnenolone given for 10 consecutive days did not show a significant effect on alcohol intake and alcohol preference.

6.

en.wikipedia.org

en.wikipedia.org/wiki/Pregnenolone

Pregnenolone

Pregnenolone (P5), or pregn-5-en-3β-ol-20-one, is an endogenous steroid and precursor/metabolic intermediate in the biosynthesis of most of the steroid ...

7.

scbt.com

scbt.com/p/pregnenolone-145-13-1?srsltid=AfmBOopuLPabNIkFFgznIkIn8FJBZmilXMZq7tQToUoJ6LOSWDafpfXe

Pregnenolone | CAS 145-13-1

Pregnenolone is an prohormone neurosteroid also a precursor to gonadal steroid hormones and the adrenal corticosteroids.

8.

amazon.com

amazon.com/Pure-Encapsulations-Pregnenolone-Hypoallergenic-Supplement/dp/B0017QADBC

Amazon.com: Pure Encapsulations Pregnenolone - 30 mg

Hormone Precursor: Pure Encapsulations Pregnenolone 30 mg aids in hormonal balance for women and men, supporting memory health and a sense of overall well ...

9.

p5js.org

p5js.org/

p5.js

p5.js.

10.

shop.bioticsresearch.com

shop.bioticsresearch.com/products/pregnenolone-25

Pregnenolone 25

Pregnenolone is an endogenous steroid hormone synthesized from cholesterol. As a "parent hormone," pregnenolone can be converted to other hormones, ...